These findings seemed to be specific to hepatic malignancies, as none of the three genes (B2M, C1qA, and SUCGL1) displayed significant variations in their expression levels across a spectrum of human brain cancers [healthy (n = 3), meningioma (n = 25), astrocytoma (n = 8), oligoastrocytoma (n = 2), oligodendroglioma (n = 5), glioblastoma multiforme (n = 2), hemangiopericytoma (n = 2) (Supplementary Figure S1)]. This evidence concerns the gene B2M and brain cancer.